Theragnostics Galli Banner

Galli® Technology

Galli® is Theragnostics’ proprietary platform for the development of single-step kits for the preparation of gallium-containing radiopharmaceuticals using the tris(hydroxypyridinone) (THP) chelator.

Galli® is Theragnostics’ proprietary platform for the development of single-step kits for the preparation of gallium-containing radiopharmaceuticals using the tris(hydroxypyridinone) (THP) chelator.

Single step “cold” kit

The Galli® technology will bring about the first cGMP Gallium-68 “cold” kit which labels quantitatively at room temperature, yielding product at physiological pH, ready for QC and injection, in under a minute and in a single step directly from a Ga-68 generator to form a single isomeric species.

The ‘cold’ kit will enable clinics, not just hospitals, to administer the product, meaning a diagnosis can be carried out far more widely and conviently for both clinicians and patients.

Our most advanced product to date, THG-001, aka Ga-68 THP-PSMA, utilizes the chelator IP, THP, at the centre of the the Galli® technology, to target the PSMA molecule to image prostate cancer. We are currently developing combinations with additional targeting molecules to broaden the range of products across cancers in both therapeutic and diagnostic applications.

The Galli® technology will bring about the first cGMP Gallium-68 “cold” kit which labels quantitatively at room temperature, yielding product at physiological pH, ready for QC and injection, in under a minute and in a single step directly from a Ga-68 generator to form a single isomeric species.

The ‘cold’ kit will enable clinics, not just hospitals, to administer the product, meaning a diagnosis can be carried out far more widely and conviently for both clinicians and patients.

Our most advanced product to date, THG-001, aka Ga-68 THP-PSMA, utilizes the chelator IP, THP, at the centre of the the Galli® technology, to target the PSMA molecule to image prostate cancer. We are currently developing combinations with additional targeting molecules to broaden the range of products across cancers in both therapeutic and diagnostic applications.

Comparison of kit-based technologies

Comparison of kit-based technologies